Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amylyx Pharmaceuticals (AMLX) Net Margin (2021 - 2024)

Amylyx Pharmaceuticals (AMLX) has 4 years of Net Margin data on record, last reported at 137.51% in Q4 2024.

  • For Q4 2024, Net Margin rose 13523.0% year-over-year to 137.51%; the TTM value through Sep 2025 reached 553.43%, up 68526.0%, while the annual FY2024 figure was 344.55%, 35690.0% down from the prior year.
  • Net Margin reached 137.51% in Q4 2024 per AMLX's latest filing, up from 17476.92% in the prior quarter.
  • Across five years, Net Margin topped out at 137.51% in Q4 2024 and bottomed at 17476.92% in Q3 2024.
  • Average Net Margin over 4 years is 3879.78%, with a median of 134.01% recorded in 2024.
  • Peak YoY movement for Net Margin: soared 985077bps in 2023, then plummeted -1750027bps in 2024.
  • A 4-year view of Net Margin shows it stood at 8120.0% in 2021, then surged by 98bps to 200.17% in 2022, then soared by 101bps to 2.28% in 2023, then skyrocketed by 5930bps to 137.51% in 2024.
  • Per Business Quant database, its latest 3 readings for Net Margin were 137.51% in Q4 2024, 17476.92% in Q3 2024, and 7106.55% in Q2 2024.